Botulinum Toxin Market is expected to reach US$ 19.03 billion by 2031

Botulinum Toxin A Segment to Contribute Significantly to Botulinum Toxin Market Growth During 2023–2031

According to our latest study on "Botulinum Toxin Market Forecast to 2031 – Global Analysis – Product, Application, and End User," the market was valued at US$ 7.38 billion in 2023 and is expected to reach US$ 19.03 billion by 2031. Factors such as the rising popularity of noninvasive aesthetic procedures and the increasing use of botulinum toxin for enhancing facial aesthetics are contributing to the growing botulinum toxin market size. However, the side effects of botulinum toxin impede the market growth.  

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. Botulinum toxins have been clinically proven to have therapeutic effects against headaches, hypersalivation, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to some surgical interventions. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins.

Botulinum Toxin Market

Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely in use in plastic and aesthetic surgeries, as these toxins are known to have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that the administration of botulinum toxin facilitates the recovery of the damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation and reducing collagen-accumulated lesions, ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxin market trends in the coming years.

Market Segmentation:

The botulinum toxin market analysis has been carried out by considering the following segments: product, application, and end user. Based on product, the market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger market share in 2023, and it is anticipated to register a higher CAGR during 2023–2031. Botulinum toxin A injections provide a minimally invasive and promising treatment option for muscle spasms, cosmetic imperfections, and other conditions. This type is also used in treating incontinence, migraine, hyperhidrosis, and blepharospasm. Its cosmetic applications include the reduction of wrinkles and fine lines on the face, especially wrinkles in the upper areas of the face, i.e., the side corners of the eyes, forehead, and glabellar lines.

By application, the market is bifurcated into medical and aesthetic. The medical segment held the largest botulinum toxin market share in 2023 and is anticipated to register the highest CAGR of 13.3% during 2023–2031. The medical segment is further categorized into chronic migraine, muscle spasm, overreactive bladder, hyperhidrosis, and others. The market for the aesthetic segment is further divided into frown lines/glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others. Botulinum toxin is a neurotoxin used to treat and manage various medical conditions, including chronic migraine, spastic disorders, cervical dystonia, and detrusor hyperactivity. Medical applications of botulinum toxin include chronic migraine, muscle spasms, overreactive bladder, and hyperhidrosis. Chronic migraine is a severely disabling neurological disorder characterized by pulsating unilateral or bilateral headaches. It is primarily described as a headache that troubles individuals for at least 15 days per month for three months. Botulinum toxin injections have also been found to be effective in treating cerebral palsy, providing patients with major relief from severe muscle contraction. Botulinum toxin A has also been studied for its effectiveness in treating chronic lower back pain.

The botulinum toxin market, by end user, is categorized into specialty and dermatology clinics, hospitals and clinics, and others. The specialty and dermatology clinics segment held the largest market share in 2023. The botulinum toxin market growth in this segment is attributed to the patients’ inclination toward dermatology clinics for their specialized dermatology treatment needs, and the ability of these clinics to provide rapid and effective services. These patients usually have specific skin conditions that require expert evaluation and management. Botulinum toxin treatments offered in dermatology clinics are tailored to address these specific concerns, with customized formulations designed to target the underlying causes of skin problems. Cosmetic procedures have become more widespread in the last 10 years. Moreover, the introduction of minimally invasive techniques has added to the popularity of dermatological procedures. Botulinum toxin injections, hyaluronic acid treatments, laser hair removal, nonsurgical fat reduction, and photorejuvenation/intense pulse light (IPL) have been the most common nonsurgical cosmetic procedures that are performed in dermatology clinics.

Botulinum Toxin Market, by Geography:

The scope of the botulinum toxin market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In terms of revenue, North America dominated the botulinum toxin market share in 2023.

Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age group of 18–65.

According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. With this approval, Allergan expanded BOTOX’s applications to treat eight new muscle conditions related to upper limb spasticity in adults.

Apart from factors driving the market, the botulinum toxin market report emphasizes on prominent players operating in the market; these include AbbVie Inc, Merz Pharma, Medytox, Ipsen Pharma, Galderma, Revance Therapeutics Inc, Lanzhou Institute of Biological Products Co Ltd, Evolus Inc, Hugel Inc, and Aquavit.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com